In a new study from Mayo Clinic and elsewhere, researchers found that delaying the second dose of COVID-19 vaccines, at least for people aged under 65, could result in up to 20% lower mortality, but only under certain conditions.
These conditions include a one-dose vaccine effectiveness (efficacy) of 80% or higher and vaccination rates of 0.1% to 0.3% of the population per day.
If these conditions apply, the researchers say the strategy could prevent between 47 and 26 deaths per 100,000 people, respectively.
Both the Pfizer and Moderna COVID-19 vaccines in a standard two-dose schedule are highly effective at preventing symptomatic infections and death.
But immunity worldwide remains low, partly owing to low vaccination rates.
The longer it takes to effectively vaccinate the global population, the greater the likely risk of vaccine-resistant strains developing.
This has led to calls to prioritize single-dose vaccination for as many people as possible, even if this means delaying a second dose beyond the studied time frame.
The justification for this relies on the assumption that meaningful protection against COVID-19 can be achieved after a single dose of vaccine, but this is the subject of intense debate.
In the study, the team set out to measure the impact of delayed second dose vaccine policies on infections, hospital admissions, and deaths compared with the current on-schedule two-dose regimen.
Using a simulation model based on a “real-world” sample population of 100,000 US adults, they ran a series of scenarios to forecast potentially infectious interactions under different conditions over a six-month period.
These included varying levels of vaccine efficacy and administration rates, and varying assumptions as to whether the vaccine prevents transmission and serious symptoms or only prevents serious symptoms, including death.
They also examined the impact of delaying second doses for those younger than 65, but not before fully vaccinating older people.
The results suggest that under specific conditions a decrease in cumulative mortality, infections, and hospital admissions can be achieved when the second vaccine dose is delayed.
The study replicated the simulations several times and used that data to estimate different population-level outcomes.
These results suggest that a delayed second dose strategy is optimal for vaccination rates at or lower than 0.3% population per day if the vaccine efficacy from one dose is 80% or greater.
What’s more, the delayed second dose strategy for people under 65 performed consistently well under all vaccination rates tested, resulting in absolute cumulative mortality reductions up to an estimated 48 per 100,000.
The team says decision-makers will need to consider their local vaccination rates and weigh the benefits of increasing these rates by delaying a second dose versus the risks associated with the remaining uncertainty in this strategy.
If you care about the COVID-19 vaccine, please read studies about what heart and stroke patients should know about COVID-19 vaccines and findings of risks vs. benefits of the COVID-19 vaccine you need to know.
For more information about the COVID-19 vaccine and your health, please see recent studies about why older people must go to the front of the COVID-19 vaccine line and results showing that why it takes 2 shots to make COVID-19 mRNA vaccines do their antibody-creating best.
The study is published in The BMJ. One author of the study is Santiago Romero-Brufau.
Copyright © 2021 Knowridge Science Report. All rights reserved.
